Results 41 to 50 of about 27,163 (253)

Network Localization of Fatigue in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo, Jaakko Kungshamn, Albert Bellmunt‐Gil, Silvia Tommasin, Abhineet Ojha, Matias Viitala, Juho Aaltonen, Jyrki Lötjönen, Juha Koikkalainen, Pauli Ylikotila, Patrizia Pantano, Merja Soilu‐Hänninen, Juho Joutsa   +12 more
wiley   +1 more source

Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis

Journal of Ophthalmic Inflammation and Infection, 2020
Background Patients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic ...
Scott Joseph Sonne, Bradley Thomas Smith
doaj   +1 more source

Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. [PDF]

PLoS ONE, 2015
In multiple sclerosis (MS) patients, Fingolimod may induce prolonged heart-rate slowing which might be caused by MS-related central autonomic lesions.To evaluate whether MS-patients with prolonged heart-rate slowing (> six hours) upon Fingolimod show ...
Max J Hilz, Tassanai Intravooth, Sebastian Moeller, Ruihao Wang, De-Hyung Lee, Julia Koehn, Ralf A Linker   +6 more
doaj   +1 more source

Safety monitoring of the newer disease modifying therapies in multiple sclerosis patients in Mater Dei hospital [PDF]

, 2016
Patients with highly active Multiple Sclerosis can be started on the newer pharmaceutical agents, Dimethyl Fumarate or Fingolimod. Safety monitoring recommended includes regular blood analysis and also ophthalmic tests and MRI scans in the case of ...
Aquilina, Josanne, Zammit, Daniela
core  

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund, Johan Reutfors, Thomas Frisell, Fredrik Piehl   +3 more
wiley   +1 more source

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Frontiers in Neuroscience, 2017
Objective: It is well-known that initiation of fingolimod induces a transient decrease of heart rate. However, the underlying cardiac autonomic regulation is poorly understood. We aimed to investigate the changes of autonomic activity caused by the first
Kai Li, Kai Li, Urszula Konofalska, Katja Akgün, Manja Reimann, Heinz Rüdiger, Rocco Haase, Tjalf Ziemssen, Tjalf Ziemssen   +8 more
doaj   +1 more source

The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. [PDF]

, 2016
OBJECTIVE: To assess longitudinally the antiviral immune response of T cells from patients with multiple sclerosis (MS) treated with fingolimod (FTY) vs other disease-modifying treatments (DMTs). METHODS: We assessed cellular immune responses specific to
Canales, M., Du Pasquier, R., Mathias, A., Perriard, G., Perrotta, G., Schluep, M., Vuilleumier, F.   +6 more
core   +1 more source

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt, Marius Ygonia, Ali Manouchehrinia, Philippe Lefrançois, Ingrid Kockum, Adil Harroud   +5 more
wiley   +1 more source

Fingolimod: therapeutic mechanisms and ocular adverse effects. [PDF]

, 2017
Fingolimod is an oral immunomodulating drug used in the management of relapsing-remitting multiple sclerosis (RRMS). We aim to review the published literature on ocular manifestations of fingolimod therapy and their possible underlying mechanisms.
A Groves, A Gupta, A Minuk, A Schwarz, AR Afshar, B Nealon, BJ McVerry, C Aguiar, D Ontaneda, G Saab, H Chen, H Tedesco-Silva, J Camm, J Chui, J Chun, JA Cohen, JA Cohen, JM Gelfand, K Schroder, K Turaka, L Kappos, L Kappos, L Liu, M Brar, M Salvadori, MA Zarbin, ML Oo, MT Bhatti, N Ueda, OJ Coppes, P A Keane, P Mandal, PA Calabresi, R Gallego-Pinazo, R Moosavi, RS Brush, S Thoo, V Li, VM Asensio-Sanchez, W Fusi-Rubiano, Y Yang   +40 more
core   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source